349 top medical experts on Mucopolysaccharidosis I across 49 countries and 27 U.S. states, including 192 MDs (Physicians). This is based on an objective analysis of their Scientific Publications, Clinical Trials, Medicare, and NIH Grants.

  1. Mucopolysaccharidosis I: Systemic lysosomal storage disease caused by a deficiency of alpha-L-iduronidase (iduronidase) and characterized by progressive physical deterioration with urinary excretion of dermatan sulfate and heparan sulfate. There are three recognized phenotypes representing a spectrum of clinical severity from severe to mild: Hurler syndrome, Hurler-Scheie syndrome and Scheie syndrome (formerly mucopolysaccharidosis V). Symptoms may include dwarfism; hepatosplenomegaly; thick, coarse facial features with low nasal bridge; corneal clouding; cardiac complications; and noisy breathing.
  2. Clinical guidelines are the recommended starting point to understand initial steps and current protocols in any disease or procedure:
  3. Broader Categories (#Experts): Mucopolysaccharidoses (1,530).
  4. Clinical Trials ClinicalTrials.gov : at least 54 including 5 Active, 24 Completed, 11 Recruiting
  5. Synonyms: Hurler's Syndrome,  Hurler-Scheie Syndrome,  Lipochondrodystrophy,  Mucopolysaccharidosis V,  Pfaundler-Hurler Syndrome,  Scheie's Syndrome


  

        

                    


    Computing Expert Listing ...

);